zentalis.com
Provided by Alexa ranking, zentalis.com has ranked N/A in N/A and 6516343rd on the world. It is hoted in N/A with IP address 99.83.190.102. The home page has 0 external link.
Top keyword related from Search Engine of zentalis.com
Traffic Ranks of zentalis.com
Owner: |
N/A |
RANK: |
6516343 |
Country code: |
N/A |
Country name: |
N/A |
Rank on country: |
N/A |
Host: |
N/A |
Ip: |
99.83.190.102 |
Ref link: |
|
Extension: |
com |
-
1. Zentalis Pharmaceuticals
Link: https://www.zentalis.com:443/
Description: WEBAbout Zentalis. Improving Patient lives. We are a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. Learn More.
-
2. About Us - Zentalis Pharmaceuticals
Link: https://www.zentalis.com:443/about/company
Description: WEBNYU Langone Health. Learn about Zentalis, an innovative oncology company focused on developing transformative cancer treatments, driven by cutting-edge research and a patient-centric approach.
-
3. Pipeline - Zentalis Pharmaceuticals
Link: https://www.zentalis.com:443/pipeline/pipeline
Description: WEBExplore Zentalis' robust pipeline of next-generation cancer therapies targeting difficult-to-treat cancers. Azenosertib is a potentially first-in-class and best-in-class oral WEE1 inhibitor in development for the treatment of advanced solid tumors. Discover our innovative approach to revolutionizing cancer care.
-
4. Press Releases | Zentalis Pharmaceuticals
Link: https://ir.zentalis.com:443/news-events/press-releases
Description: WEBApr 02, 2024. Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024. Apr 01, 2024.
-
5. Zentalis Pharmaceuticals Announces Updates Across its Pipeline
Link: https://ir.zentalis.com:443/news-releases/news-release-details/zentalis-pharmaceuticals-announces-updates-across-its-pipeline/
Description: WEBZentalis is planning to launch a biomarker-driven Phase 2 study pending FDA feedback. The tumor-agnostic trial will investigate ZN-c3 in patients with solid tumors that express the identified predictive biomarker, and is expected to initiate by year-end.
-
6. Investors/Media Home | Zentalis Pharmaceuticals
Link: https://ir.zentalis.com:443/
Description: WEBZentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. Recent News. Learn More.
-
7. Zentalis Pharmaceuticals Announces Positive Initial Clinical Data …
Link: https://ir.zentalis.com:443/news-releases/news-release-details/zentalis-pharmaceuticals-announces-positive-initial-clinical
Description: WEBNEW YORK and SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced initial efficacy and …
-
8. Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial …
Link: https://ir.zentalis.com:443/news-releases/news-release-details/zentalis-pharmaceuticals-reports-third-quarter-2023-financial
Description: WEBNov 6, 2023 · Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate, azenosertib (ZN-c3), is a potentially first-in …
-
9. Zentalis Pharmaceuticals Announces First Patient Dosed in …
Link: https://ir.zentalis.com:443/news-releases/news-release-details/zentalis-pharmaceuticals-announces-first-patient-dosed/
Description: WEBZentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma | Zentalis Pharmaceuticals. Skip to main navigation. . About Us. Our Company. OverviewManagement TeamBoard of DirectorsScientific Advisory BoardPartners & Collaborations. Contact. Our Pipeline.
-
10. Clinical Trials - Zentalis Pharmaceuticals
Link: https://www.zentalis.com:443/pipeline/clinical-trials
Description: WEBZentalis Pharmaceuticals is currently conducting clinical studies evaluating its small molecule therapeutics. Learn about and participate in groundbreaking clinical trials to help advance the development of novel cancer therapies.